Therefore, these results suggest that combination treatment of Sunitinib and CTLA‐4 mAb can be potential as a novel therapeutic strategy for the treatment of human melanoma and NSCLC. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.